Login / Signup

Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?

Neesha RockwoodMaddalena CerroneMelissa BarberAndrew M HillAnton L Pozniak
Published in: Journal of the International AIDS Society (2020)
Rifabutin should be available globally as a first-line rifamycin in HIV co-infected individuals and as a switch option in cases of rifampicin associated ADRs. Further studies are needed to ascertain the utility of rifabutin in rifampicin-resistant rifabutin-susceptible TB.
Keyphrases